RA Capital

RA Capital Management is a Boston-based investment firm focused exclusively on healthcare, biotechnology, and what it calls planetary health, with a portfolio that spans drugs, medical devices, diagnostics, research tools, and healthcare services across both private and public markets. Founded in 2001 by Richard Aldrich, a co-founder of Vertex Pharmaceuticals, and formally established in 2004, RA Capital has grown into one of the most influential crossover investors in biotech, with disclosed public holdings of approximately $9.8 billion and a private portfolio of more than 100 active companies. The firm’s distinctive structure combines a long-only and crossover public equity strategy with a venture and crossover private investment franchise, allowing RA Capital to seed companies, support them through clinical milestones, anchor crossover financings, and continue to hold them through and after IPO.

Peter Kolchinsky, a Founder and Managing Partner, is the public face of the firm and one of the most recognized voices in biotech investing. Kolchinsky joined Aldrich in 2002 with a Harvard PhD in virology and $4 million in seed money to invest, and he has built RA Capital into a franchise that combines deep scientific rigor with a willingness to write substantial checks at multiple stages. He serves on the boards of multiple public and private life sciences companies and has been a vocal commentator on drug pricing, the biotech social contract, and policy issues facing the industry. Other senior partners include Andrew Levin, who co-anchors the private investment franchise, and a broad bench of MDs, PhDs, and senior investors with operating and clinical backgrounds across therapeutics areas.

The RA Capital portfolio reads like a who’s who of validated and emerging biotech: across small molecules, biologics, cell and gene therapy, RNA therapeutics, gene editing, oncology, immunology, neurology, cardiometabolic, rare disease, and platform biology. The firm has been a consistently important crossover investor, frequently anchoring the late-private rounds that bridge to IPO. RA Capital also operates a TechAtlas internal research platform that produces deep dives on therapeutic areas and disease landscapes, which gives the firm an unusual depth of pattern matching across categories.

Check sizes are wide. At early venture stages, RA Capital typically writes $5 million to $25 million; at Series B and C, $25 million to $75 million; and at crossover, $25 million to $100 million plus, frequently anchoring the round. The firm leads and co-leads at all stages and is one of the few healthcare-only firms that can credibly support a company from seed through IPO and into the public markets. Geographic scope is global with US and European centers of gravity, and the firm has been increasingly active in cross-border deals.

Founders who should approach RA Capital are scientific founders with novel therapeutic assets or platforms, repeat biotech operators, and operators building healthcare services and infrastructure with a clear clinical or scientific differentiation. The firm is particularly well suited for founders who envision raising substantial capital across multiple rounds and who want a partner with crossover capability to anchor their late-private and IPO transitions. Founders building consumer DTC, non-clinical SaaS, devices without strong clinical evidence, or pre-clinical assets without a credible mechanism story should pitch other firms. Founders should also be prepared for rigorous scientific and clinical diligence; RA Capital is famously thorough and analytical.

Entry path runs through warm introductions from portfolio CEOs, scientific advisors, and peer specialist investors. The firm is heavily present at JPMorgan Healthcare, BIO, AACR, ASCO, ASH, and the major scientific conferences. Kolchinsky is publicly active and reachable through writing, podcasts, and conferences. Cold inbound through the website is triaged. Diligence is rigorous and partner-driven, often including extensive review by the TechAtlas research team, typically four to eight weeks from first meeting to term sheet for novel platforms.

In a pitch, lead with the science, the unmet need, the competitive landscape (RA Capital partners will know it deeply), the IP estate, and the clinical and regulatory plan. The firm’s partners are MDs, PhDs, and trained scientists; they will probe your translational data, your competitive positioning, and your manufacturing and scale-up plan in detail. Bring credible senior leadership and a clear path from current data to a value-creating inflection. The firm’s added value is best realized when founders use the full RA Capital platform: TechAtlas research, the firm’s deep scientific advisor network, and the crossover public-equity teams that can anchor IPO and post-IPO financings. Founders building toward IPO scale who want a partner that can think across the full lifecycle will find RA Capital one of the most powerful tier-one investors in biotech.